Cilostazol increases patency and reduces adverse outcomes in percutaneous femoropopliteal revascularisation: a meta-analysis of randomised controlled trials

BACKGROUND: Cilostazol is an oral antiplatelet agent currently indicated for treatment of intermittent claudication. There is evidence that cilostazol may reduce femoropopliteal restenosis after percutaneous endovascular intervention. METHODS: We searched PubMed, Scopus and Cochrane databases from 1...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Heart
Hlavní autoři: Benjo, Alexandre M, Garcia, Daniel C, Jenkins, J Stephen, Cardoso, Rhanderson M N, Molina, Taina P, El-Hayek, Georges E, Nadkarni, Girish N, Aziz, Emad F, Dinicolantonio, James J, Collins, Tyrone
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2014
Témata:
Meta-Analysis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4225296/
https://ncbi.nlm.nih.gov/pubmed/25392738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/openhrt-2014-000154
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky